Back to News
Market Impact: 0.22
Diasome Pharmaceuticals to Present HDV-Insulin Phase 2b Clinical Data at EASD 2026 and Inaugural Breakthrough T1D Clinical & Research Congress
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
Phase 2b OPTI-2 findings will be presented showing that HDV-insulin lispro may maintain glycemic control while reducing hypoglycemia in adults with type 1 diabetes. The results are clinically encouraging but remain mid-stage trial evidence, with no efficacy statistics, regulatory milestones, or commercialization details provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Meta's Muse personal AI agent tops ChatGPT, Grok and Claude for post-launch downloads
- Muse, Meta's extraordinarily privileged AI assistant, has a serious 0-day
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Why is Labcorp stock sliding today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit
- AI Research Systems for Hedge Funds: A Pilot Design